Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Jun 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new form of medication called Advagraf, which is a type of drug used to prevent the body from rejecting a kidney transplant. Currently, many patients take a medicine called tacrolimus right after their transplant, but it can sometimes harm the kidneys or increase the risk of diabetes. Advagraf is a newer, slow-release version of tacrolimus that may have fewer side effects. The trial aims to see how this new medication works in the short term after a kidney transplant.

People who have had a kidney transplant may be eligible to join this study, as long as they have not had a combined kidney and pancreas transplant, are not very overweight (BMI over 30), and do not have certain immune system factors (cPRA over 0%). Participants will take the new medication and be monitored to see how well it works and if it causes any problems. This study is currently looking for volunteers between the ages of 65 and 74, and both men and women can join. If you or a loved one fits these criteria, this trial could be an option to help improve care after a kidney transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All Kidney transplant recipients
• Exclusion Criteria:
• • Kidney-Pancreas transplant BMI\>30 cPRA\>0%